With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but ...
A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage ...
Last November, Pyxis revealed it would continue to focus on PYX-201 as its lead asset, while pausing other early-stage ...
Srinagar- Head and neck cancers are on the rise in Kashmir, with Srinagar and Anantnag districts showing the highest number ...
BofA Securities, TD Cowen, Stifel, Cantor and William Blair are acting as joint book-running managers for the offering. Wedbush PacGrow, LifeSci Capital, BTIG and Jones are acting as co-managers for ...
Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data ...
Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report.
Compared to normal tissues, where the expression of ULBP2/5/6 protein is restricted, in non-small-cell lung cancer (NSCLC), head and neck cancer and squamous urothelial carcinoma, the levels of ...